Sulfasalazine for metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the drug sulfasalazine to standard chemotherapy can help people with metastatic colorectal cancer live longer. It is for patients whose cancer has spread and who are healthy enough for chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have metastatic colorectal cancer (stage IV) that has been confirmed by a biopsy.
- You should be between 18 and 65 years old.
- You must be in generally good health (able to do daily activities) and not have severe bone marrow suppression.
- Your liver and kidney function must be adequate (your doctor will check this).
- You cannot be pregnant or breastfeeding, and you must use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SSGJ-707 for people with colorectal cancer that has spread. It aims to see if the drug can help shrink or control the cancer.
This trial is for people with colorectal cancer that has spread to the liver. It tests whether adding a new drug (sotevtamab) to standard chemotherapy (FOLFOX) before surgery can help shrink tumors and improve outcomes.
This Phase 1/2 trial studies whether sulfasalazine, added to intensive chemotherapy, can help older adults with newly diagnosed acute myeloid leukemia (AML). It aims to improve treatment effectiveness and track leukemia “leftover cells” in some participants.
This trial tests whether adding an EGFR-targeting antibody to chemotherapy can help people with colorectal cancer that has spread to the liver. It's for those whose tumors have a normal RAS gene and who have not had treatment before.
This trial tests a combination of three drugs—savolitinib, cetuximab, and chemotherapy (FOLFOX)—for people with advanced colorectal cancer that has certain genetic features (RAS/BRAF wild-type and c-MET positive). It may help shrink tumors or slow their growth.
This trial tests two different chemotherapy regimens (FOLFOX8 and mFOLFOX6), each paired with a targeted drug (bevacizumab or cetuximab), to treat colorectal cancer that has spread and cannot be surgically removed. The goal is to find which combination works best as a first treatment.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.